Cuprina to Acquire Seven-Clinic Singapore Healthcare Group for S$4.0M
CUPR sits 81% above its 52-week low of $1.445.
Summary
Cuprina Holdings agreed to acquire a seven-clinic Singapore healthcare group for S$4.0M (~US$3.1M), paying 75% cash and 25% in stock. The target generated S$9.1M revenue and S$1.2M EBITDA in FY2025, and completion is expected by November 1, 2026.
Key Events · M&A and Partnerships · CUPR
-
Acquires Seven-Clinic Healthcare Group
Cuprina's BVI subsidiary entered SPAs on October 1, 2026 to acquire 100% of East Coast Podiatry Centre (five clinics) and Orchard Clinic Management (two clinics) for approximately S$4.0 million (~US$3.1 million).
-
Consideration: 75% Cash, 25% Stock
S$3.0 million payable in cash (S$0.5M on execution, S$1.35M at closing, S$1.15M deferred over two years) and S$1.0 million in 301,671 Class A shares priced at S$3.31 each, representing ~3.79% of the enlarged share count.
-
Target Financials: S$9.1M Revenue, S$1.2M EBITDA
The Target Group generated unaudited FY2025 revenue of S$9.1 million (~US$7.0M) and normalized EBITDA of S$1.2 million (~US$0.9M), implying a purchase multiple of roughly 3.3x EBITDA.
-
Completion Tied to October 15 EGM
Closing is expected on or before November 1, 2026, conditioned on shareholder approval of the authorized share capital increase at the Extraordinary General Meeting on October 15, 2026.
Analysis · CUPR · Industrial Applications And Services
Cuprina is acquiring 100% of East Coast Podiatry Centre and Orchard Clinic Management for approximately S$4.0 million (~US$3.1 million), paid 75% in cash and 25% in newly issued Class A shares. The Target Group generated S$9.1 million in unaudited FY2025 revenue and S$1.2 million in normalized EBITDA — meaning Cuprina is paying roughly 3.3x EBITDA for a profitable, cash-generating clinical platform. This is a transformative deal for a company with a market cap of only ~US$13.4 million: it roughly doubles the revenue base and adds an established podiatry and women's health network directly aligned with Cuprina's wound-care and collagen technologies. The deal is conditional on shareholder approval of the pending 100x authorized share increase at the October 15 EGM, tying this acquisition directly to the company's aggressive capital restructuring. The 301,671 Consideration Shares represent approximately 3.79% of the enlarged share count, adding modest dilution on top of the recent 4.97M-share offering and over-allotment exercise.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.3% of the 1065 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CUPR was trading at $2.62 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $13.4M. The 52-week trading range was $1.45 to $14.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.